Aprea Therapeutics updates patent portfolio for ATR and WEE1 inhibitor programs

Aprea Therapeutics, Inc.

ATR inhibitor program: 4 granted US patents, 1 pending US application, 1 provisional; 19 granted non-US patents, 16 pending non-US applications.
Granted patents expire 2035-2037; pending applications may extend exclusivity to 2044.
Lead ATR inhibitor ATRN-119 in Phase 1 ABOYA-119 trial for solid tumors with DDR mutations.
WEE1 inhibitor program: 1 pending US application, 12 pending non-US applications; if granted, expire 2043.
Lead WEE1 inhibitor APR-1051 in Phase 1 ACESOT-1051 trial for advanced/metastatic solid tumors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.